Proteomics, Personalized Medicine and Cancer

Su, Miao; Zhang, Zhe; Zhou, Li; Han, Chao; Huang, Canhua; Nice, Edouard C.

SIMPLE SUMMARY: Cancer, a major public health issue worldwide, is the second most common cause of death. Initiatives such as the Human Genome Project (HGP) and Human Proteome Project (HPP) have greatly advanced the understanding of human health and disease, including cancer, and are supporting the current trend towards personalized/precision medicine. In this review, we will overview recent technological achievements, the key hallmarks of cancer, and unmet clinical needs. We will specifically detail the importance of cancer biomarkers in diagnosis and treatment, the role of the microbiome in health and disease, the potential of emerging omics technologies and the goals of personalized/precision medicine. Finally, we will discuss future perspectives, both from the standpoint of perceived advances in treatment, but also from the hurdles that have to be overcome. ABSTRACT: As of 2020 the human genome and proteome are both at >90% completion based on high stringency analyses. This has been largely achieved by major technological advances over the last 20 years and has enlarged our understanding of human health and disease, including cancer, and is supporting the current trend towards personalized/precision medicine. This is due to improved screening, novel therapeutic approaches and an increased understanding of underlying cancer biology. However, cancer is a complex, heterogeneous disease modulated by genetic, molecular, cellular, tissue, population, environmental and socioeconomic factors, which evolve with time. In spite of recent advances in treatment that have resulted in improved patient outcomes, prognosis is still poor for many patients with certain cancers (e.g., mesothelioma, pancreatic and brain cancer) with a high death rate associated with late diagnosis. In this review we overview key hallmarks of cancer (e.g., autophagy, the role of redox signaling), current unmet clinical needs, the requirement for sensitive and specific biomarkers for early detection, surveillance, prognosis and drug monitoring, the role of the microbiome and the goals of personalized/precision medicine, discussing how emerging omics technologies can further inform on these areas. Exemplars from recent onco-proteogenomic-related publications will be given. Finally, we will address future perspectives, not only from the standpoint of perceived advances in treatment, but also from the hurdles that have to be overcome.